Practical Application of PET-Adapted Therapy in Hodgkin Lymphoma

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: February 28, 2018
Expiration Date: February 28, 2019

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

The utilization of interim positron emission tomography (PET) imaging to guide therapeutic decisions has the potential to further individualize therapy, avoid unnecessary treatment and associated toxicity, and optimize outcomes for patients with Hodgkin lymphoma (HL). In this activity, participants will learn about the different PET-adapted strategies being investigated in HL, with a focus on the interpretation of data for the practical use of interim PET, to help providers evaluate the current clinical evidence and applicability to their practice.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in Hodgkin lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe PET-adapted treatment strategies and algorithms under investigation for patients with Hodgkin lymphoma (HL)
  • Explain the impact of clinical evidence related to PET-adapted therapy in patients with HL, differentiating practice-changing data

Agenda

Practical Application of PET-Adapted Therapy in Hodgkin Lymphoma – Matthew Matasar, MD

Instructions for Participation and Credit

This activity is eligible for credit through February 28, 2019. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Matthew Matasar, MD
Lymphoma and Adult BMT Services
Director, Lymphoma Survivorship Clinic
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Matthew Matasar, a board-certified medical oncologist/hematologist, received his medical degree from Harvard University. His internal medicine training was completed at Columbia Presbyterian, where he earned a master’s in biostatistics, and served as chief resident. His fellowship training was in medical oncology at Memorial Sloan Kettering Cancer Center, where he subsequently joined faculty on the Lymphoma and Adult BMT Services. Dr. Matasar is also the Director of the Lymphoma Survivorship Clinic, where he focuses on the management of long-term survivors of Hodgkin and non-Hodgkin lymphoma. As a member of the lymphoma and BMT services, his research is aimed to explore the management of aggressive lymphomas, focusing on improving outcomes in relapsed but curable patients using novel therapy and stem cell transplantation techniques. His primary research interest is in developing a research program to better understand the optimal care of lymphoma survivors, focusing on reducing the risk and improving the management of late effects of chemotherapy and radiation therapy.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-001-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Mathew Matasar has disclosed no relevant financial relationships.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Merck & Co., Inc., Seattle Genetics, and Takeda Oncology.

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Managing HL would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support of ManagingHodgkinLymphoma.com in 2018.

©2018 MediCom Worldwide, Inc. All rights reserved